At a Glance
- Company: Replimune Group
- Location: Massachusetts, US
- Layoffs: 63 employees
- Trigger: Second FDA rejection of RP1 (vusolimogene oderparepvec)
- Next steps: Cost cuts, manufacturing scaleback
What happened?
Replimune Group received a Complete Response Letter (CRL) from the FDA on 10 April 2026 rejecting its resubmitted Biologics License Application (BLA) for RP1 in combination with Opdivo (nivolumab) for advanced melanoma. The FDA cited insufficient evidence of effectiveness from the Phase 1/2 IGNYTE trial, leading to organisational changes including layoffs of 63 employees notified on 13 April.
Why does it matter?
This marks the second rejection for RP1 — first in July 2025 — casting doubt on its viability and forcing Replimune to explore strategic alternatives amid a cash runway of under $200 million. Shares plunged over 60% post-news, highlighting risks of single-arm trials for accelerated approval in immuno-oncology where distinguishing add-on benefits remains challenging.
Who’s behind it?
Replimune develops oncolytic immunotherapies; RP1 is an engineered herpes simplex virus designed to selectively infect tumour cells, express GM-CSF and block PD-L1 to boost anti-tumour immunity. CEO Sushil Patel criticised the FDA for inconsistent review teams and lack of flexibility despite 34% ORR and 24.8-month median duration in post-anti-PD1 patients.
How was it achieved?
The CRL from a new review team (post-Richard Pazdur’s retirement) deemed IGNYTE data inadequate due to single-arm design, patient heterogeneity and inability to isolate RP1’s effect from Opdivo. Replimune disputes this, noting prior team interactions and specialist support, but must now implement cost reductions including US manufacturing cuts.
What’s next?
Replimune will evaluate RP1’s future, potentially pivoting to other pipeline assets or partnerships while pursuing efficiencies. Analysts anticipate further headcount reductions and possible sale or acquisition as the company navigates a “challenging path forward.”
What are people saying?
CEO Sushil Patel: “Deeply disappointing that the FDA has not exercised regulatory flexibility… given the data supporting strong efficacy.” BMO Capital: “Replimune faces a challenging path forward.”